Loading market dashboard
Chemomab Therapeutics Ltd.
CMMBHealthcareNASDAQIL
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update.
2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.
